Compare Futu Holdings Ltd (FUTU) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Illumina, Inc. — how do they compare? Futu Holdings Ltd trades at $113.47 (market cap $15.25B), while Illumina, Inc. trades at $277.61 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 2.6× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.39% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Illumina, Inc. for 83 Days on average.
| FUTU | ILMN | |
|---|---|---|
Market Cap | $15.25B | $39.95B |
Volume | 812,567 | 3,169,503 |
Sector | Financials | Health |
52-Week High | $199.04 | $293.69 |
52-Week Low | $89.76 | $91.00 |
Typical Hold Time | 34 Days | 83 Days |
Enterprise Value | $15.59B | $41.31B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU trades at $113.71, up 3.67% today, with a bearish technical signal but strong fundamentals including a 10.86 P/E ratio and 42.92% net margin. Revenue grew to $22.85B in 2025, and cash flow surged to $31.02B in 2024. Recent news highlights expansion efforts like the Moomoo X partnership and a class action lawsuit deadline.
The outlook is mixed: analysts see a 33.7% upside (Zacks, 2026-09-10), but technicals and legal risks weigh. Investment opportunity lies in valuation and growth; risks include lawsuit uncertainty and competitive pressures. Earnings beat in Q2 2026 supports momentum, but Q1 2026 miss shows volatility.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
